This document summarises the current challenges with Pancreatic Enzyme Replacement Therapy supply (PERT) and provides advice and actions for prescribers, patients and community pharmacy.
Summary of current issues:
There are limited supplies of pancreatic enzyme replacement therapies in the UK:
- Creon® 10,000 capsules, Creon® 25,000 capsules and Creon® Micro Pancreatin 60.12mg gastro-resistant granules are available currently but in limited, capped quantities until 2026:
- Supply disruption is due to limited availability of the active pharmaceutical ingredients and manufacturing constraints.
- Nutrizym® 22 capsules are intermittently available but are unable to support increased demand:
- Supply disruption is caused by a manufacturing issue and increased demand due to reduction in Creon® supply.
- Pancrex® V capsules and powder are subject to supply disruption:
- Supply disruption is caused by increased demand due to reduction in Creon® preparation supply.
Two National Patient Safety Alerts (NPSA) have been issued for the Shortage of Pancreatic enzyme replacement therapy (PERT) in May 2024 and December 2024, alongside Serious Shortage Protocols (SSPs) for two pancreatic enzyme products; Creon® 25,000 capsules and Creon® 10,000 capsules.
The current status of pancreatic enzyme supplies can be checked on the SPS website.
References
- National Patient Safety Alert for the shortage of PERT – 24th May 2024
- National Patient Safety Alert – Additional Actions – 18th December 2024
- Serious Shortage Protocols for PERT – 24th May 2024
- Position Statement: PERT Shortage – 17th November 2024
- Prescribing and Ordering Available PERT – SPS – updated 9th January 2025
V1.1 approved by Integrated Medicines Optimisation Committee (IMOC) on January 2025 (Acknowledgement Surrey Heartlands ICB)